Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Cao, Q; Song, ZS; Ruan, HL; Wang, C; Yang, X; Bao, L; Wang, KS; Cheng, G; Xu, TB; Xiao, W; Xiong, ZY; Liu, D; Yang, M; Zhou, DW; Yang, HM; Chen, K; Zhang, XP

Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Urol, Tongji Med Coll, Wuhan, Peoples R China.; Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Urol, Wuhan, Peoples R China.; Yang, HM (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China.; Chen, K (corresponding author), Huazhong Univ Sci & Technol, Jiefang Ave 1277, Wuhan 430022, Peoples R China.

CLINICAL CANCER RESEARCH, 2020; 26 (6): 1516

Abstract

Purpose: Emerging evidence indicates that castration-resistant prostate cancer (CRPC) is often driven by constitutively active androgen receptor (AR) ......

Full Text Link